MacroGenics (MGNX) Competitors $1.69 +0.25 (+17.36%) Closing price 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.36%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. AQST, YMAB, HUMA, VIGL, EOLS, CYRX, MBX, CMPX, ESPR, and ATXSShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Aquestive Therapeutics (AQST), Y-mAbs Therapeutics (YMAB), Humacyte (HUMA), Vigil Neuroscience (VIGL), Evolus (EOLS), CryoPort (CYRX), MBX Biosciences (MBX), Compass Therapeutics (CMPX), Esperion Therapeutics (ESPR), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Its Competitors Aquestive Therapeutics Y-mAbs Therapeutics Humacyte Vigil Neuroscience Evolus CryoPort MBX Biosciences Compass Therapeutics Esperion Therapeutics Astria Therapeutics MacroGenics (NASDAQ:MGNX) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability. Does the media refer more to MGNX or AQST? In the previous week, MacroGenics had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 13 mentions for MacroGenics and 10 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.07 beat MacroGenics' score of 0.32 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MGNX or AQST? MacroGenics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Do analysts rate MGNX or AQST? MacroGenics presently has a consensus price target of $3.60, indicating a potential upside of 113.02%. Aquestive Therapeutics has a consensus price target of $10.14, indicating a potential upside of 154.85%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.57Aquestive Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has preferable valuation and earnings, MGNX or AQST? Aquestive Therapeutics has lower revenue, but higher earnings than MacroGenics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$149.96M0.71-$66.97M-$0.57-2.96Aquestive Therapeutics$44.13M8.99-$44.14M-$0.70-5.69 Do institutionals and insiders have more ownership in MGNX or AQST? 96.9% of MacroGenics shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 13.0% of MacroGenics shares are held by company insiders. Comparatively, 8.4% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is MGNX or AQST more profitable? MacroGenics has a net margin of -21.99% compared to Aquestive Therapeutics' net margin of -147.38%. Aquestive Therapeutics' return on equity of 0.00% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-21.99% -40.24% -14.62% Aquestive Therapeutics -147.38%N/A -63.87% SummaryMacroGenics beats Aquestive Therapeutics on 9 of the 17 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$106.83M$10.85B$5.82B$9.74BDividend YieldN/A1.88%3.84%4.09%P/E Ratio-2.9620.9331.1525.97Price / Sales0.7129.96475.57123.18Price / CashN/A24.6537.1558.38Price / Book2.283.509.116.39Net Income-$66.97M$211.77M$3.26B$265.66M7 Day Performance6.96%4.44%2.11%1.98%1 Month Performance9.74%10.98%5.12%1.33%1 Year Performance-49.25%-8.36%31.25%21.15% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics4.4344 of 5 stars$1.69+17.4%$3.60+113.0%-60.0%$106.83M$149.96M-2.96430Gap UpAQSTAquestive Therapeutics2.3394 of 5 stars$3.86-1.0%$10.14+162.8%-15.9%$387.38M$57.56M-6.54160Analyst RevisionYMABY-mAbs Therapeutics2.1246 of 5 stars$8.52+0.1%$11.16+31.0%-38.4%$385.36M$87.68M-17.04150HUMAHumacyte2.402 of 5 stars$1.75-29.4%$11.71+569.4%-76.2%$384.70M$1.57M-2.54150Insider TradeHigh Trading VolumeVIGLVigil Neuroscience1.9236 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340Positive NewsEOLSEvolus4.1146 of 5 stars$5.77-2.2%$21.25+268.3%-52.6%$381.64M$266.27M-5.89170CYRXCryoPort3.7534 of 5 stars$8.09+7.0%$12.00+48.3%-6.7%$379.04M$228.38M6.081,186MBXMBX Biosciences2.6402 of 5 stars$11.26-7.4%$37.63+234.1%N/A$376.35MN/A-2.4836CMPXCompass Therapeutics2.7856 of 5 stars$3.34+23.7%$12.67+279.2%+135.3%$373.36M$850K-8.1520High Trading VolumeESPREsperion Therapeutics3.6068 of 5 stars$1.85-1.3%$7.00+279.4%+21.0%$370.63M$332.31M-3.77200ATXSAstria Therapeutics2.9519 of 5 stars$6.68+6.4%$29.00+334.1%-46.8%$354.41MN/A-3.5730 Related Companies and Tools Related Companies Aquestive Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Humacyte Alternatives Vigil Neuroscience Alternatives Evolus Alternatives CryoPort Alternatives MBX Biosciences Alternatives Compass Therapeutics Alternatives Esperion Therapeutics Alternatives Astria Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access